ClinicalTrials.gg
Not yet recruitingNCT07950293Young MindUpdated Nov 20, 2026

Effects of MIND Diet on Brain Fog, Stress, and Sleep Quality in Young Adults

An interventional study of Mind Diet and Mediterranean Diet in Dietary Intervention, Brain Fog and Perceived Stress, sponsored by Halic University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Halic University · Not applicable, Interventional, and Other

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 22 studies in Mental Fatigue with a site in Turkey — 5 open to participants now, 5 under way, none of them phase 3. Mental Fatigue · Turkey.

Planned enrollment
9th of 18
42 · median 37
Started
2026
with 5 others
No phase
18 of 22
4 open now
Registered
22nd of 22
by date
Lead sponsor
1 of 22
Halic University

Among the 22 studies in Mental Fatigue with a site in Turkey, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is one of 6 that started in 2026, is one of 18 with no phase, and was the 22nd registered.

Mental Fatigue

177 studies on the registry are indexed under Mental Fatigue; 54 are open to participants now.

Browse Mental Fatigue studies →

Open to participants now

5 of the 22 studies in Mental Fatigue with a site in Turkey are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 30 Mental Fatigue studies recruiting now, 9 (30%) set no upper age limit and 20 (67%) stop at 75 or younger; 1 takes children under 18; 16 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Mental Fatigue with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to evaluate the effects of a MIND diet-based nutritional intervention on brain fog, perceived stress, sleep quality, and selected biochemical parameters in young adults. It will also compare the effects of the MIND diet with those of the Mediterranean diet and usual dietary habits.

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) is a dietary pattern that combines elements of the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets. It emphasizes the consumption of green leafy vegetables, other vegetables, berries, nuts, whole grains, legumes, fish, poultry, and olive oil, while limiting foods high in saturated fat, processed foods, and sweets. The Mediterranean diet similarly emphasizes plant-based foods, olive oil, whole grains, legumes, vegetables, fruits, nuts, and fish.

Young adults aged 18-35 years who meet the study eligibility criteria will be included. Participants will be randomly assigned to one of three groups: a MIND diet intervention group, a Mediterranean diet intervention group, or a control group.

Participants in the MIND diet group will receive nutritional guidance and follow a MIND diet-based dietary plan for 12 weeks. Participants in the Mediterranean diet group will receive nutritional guidance and follow a Mediterranean diet-based dietary plan for the same period. Participants in the control group will continue their usual dietary habits without receiving a structured dietary intervention during the study period.

Assessments will be conducted at baseline and at the end of the 12-week intervention. These assessments will include brain fog, perceived stress, sleep quality, dietary intake, and anthropometric measurements. Brain fog, perceived stress, and sleep quality will be evaluated using standardized assessment questionnaires. Dietary intake and adherence to the assigned dietary patterns will also be monitored throughout the intervention.

Selected biochemical parameters, including fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, liver enzymes, uric acid, urea, and creatinine, will be assessed through blood samples.

The study will investigate whether following the MIND or Mediterranean dietary pattern for 12 weeks is associated with changes in brain fog, perceived stress, sleep quality, and selected biochemical parameters in young adults. The findings may contribute to a better understanding of the relationship between dietary patterns and cognitive, psychological, sleep-related, and metabolic health.

Read the detailed description

### Detailed Description

The MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet is a dietary pattern developed by combining elements of the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH) diet. It emphasizes foods that may support brain and metabolic health, including green leafy vegetables, other vegetables, berries, nuts, whole grains, legumes, fish, and poultry, while limiting the consumption of foods high in saturated fat, processed foods, sweets, and fried foods.

The Mediterranean diet is characterized by a high intake of vegetables, fruits, legumes, whole grains, nuts, seeds, and olive oil, with regular consumption of fish and moderate consumption of other animal-based foods. Both dietary patterns emphasize minimally processed, nutrient-dense foods and a balanced dietary approach.

This study is designed as a 12-week, randomized, parallel-group, three-arm interventional trial involving young adults aged 18-35 years. The study will compare the effects of a MIND diet-based nutritional intervention and a Mediterranean diet-based nutritional intervention with a control group that will maintain its usual dietary habits.

Participants assigned to the MIND diet group will receive individualized nutritional counseling and a dietary plan based on MIND diet principles. The intervention will emphasize the regular consumption of green leafy vegetables, other vegetables, berries, nuts, legumes, whole grains, fish, and poultry, while encouraging the limitation of foods associated with lower adherence to the MIND dietary pattern.

Participants assigned to the Mediterranean diet group will receive individualized nutritional counseling and a dietary plan based on Mediterranean diet principles. The intervention will emphasize vegetables, fruits, legumes, whole grains, olive oil, nuts, seeds, and fish as important components of daily and weekly food consumption.

Dietary plans will be individualized according to participants' age, sex, physical activity level, and estimated energy requirements. Participants in both intervention groups will receive nutritional guidance throughout the 12-week study period. Dietary adherence and food consumption will be monitored at 15-day intervals using dietary records, including three-day food consumption records, and adherence assessments.

Participants in the control group will not receive a structured dietary intervention and will be asked to maintain their usual dietary habits during the study period.

Baseline assessments will be performed before the dietary interventions begin. At the end of the 12-week intervention, the assessments will be repeated to evaluate changes over time.

The primary areas of assessment include brain fog, perceived stress, and sleep quality. Brain fog will be assessed using the Brain Fog Scale, perceived stress using the Perceived Stress Scale (PSS-10), and sleep quality using the Pittsburgh Sleep Quality Index (PSQI).

Anthropometric and body composition measurements will also be obtained, including body weight, height, body mass index (BMI), and body composition assessed by bioelectrical impedance analysis.

Fasting blood samples will be collected to evaluate selected biochemical parameters, including fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid, urea, and creatinine.

The study aims to determine whether a 12-week MIND diet-based or Mediterranean diet-based nutritional intervention is associated with changes in brain fog, perceived stress, sleep quality, anthropometric measurements, and selected biochemical parameters in young adults. Comparisons between the three study groups will be used to evaluate the potential effects of the dietary interventions.

03

Conditions studied

  • Dietary Intervention
  • Brain Fog
  • Perceived Stress
  • Sleep Quality

Keywords

  • MIND Diet
  • Mediterranean Diet
  • Brain Fog
  • Perceived Stress
  • Sleep Quality
  • Young Adults
  • Nutrition
  • Cognitive Function
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-35 years.
  • Willingness to participate in the study and provide written .
  • Ability and willingness to follow the assigned dietary intervention for 12 weeks.
  • Ability to complete dietary records and study questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Presence of chronic diseases requiring a specific medical nutrition therapy.
  • Pregnancy or breastfeeding.
  • Food allergies or intolerances that prevent adherence to the study diets.
  • Following a medically prescribed or restrictive diet.
  • Regular use of medications that may significantly affect the study outcomes.
  • Any condition that may interfere with participation in the study or adherence to the intervention.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Mind Diet Group

    Participants will receive a 12-week dietary intervention based on the MIND diet.

    Behavioral: Mind Diet

  • Experimental
    Mediterranean Diet Group

    Participants will receive a 12-week dietary intervention based on the Mediterranean diet.

    Behavioral: Mediterranean Diet

  • No intervention
    Control Group

    Participants will not receive a specific dietary intervention during the 12-week study period.

Interventions

  • BehavioralMind Diet

    Participants will receive a 12-week dietary intervention based on the MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet. The intervention will include individualized dietary guidance, regular nutritional counseling, dietary monitoring, and adherence assessments throughout the study period.

  • BehavioralMediterranean Diet

    Participants will receive a 12-week dietary intervention based on the Mediterranean diet. The intervention will include individualized dietary guidance, regular nutritional counseling, dietary monitoring, and adherence assessments throughout the study period.

06

What researchers measure

Primary outcomes

  1. Change in Brain Fog Scale Score

    Brain fog will be assessed using the 23-item Brain Fog Scale. The total score ranges from 0 to 92. Higher scores indicate more severe brain fog symptoms and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in Pittsburgh Sleep Quality Index Scores

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21. Higher scores indicate poorer sleep quality and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

    Time frame: 12 weeks

  2. Change in Perceived Stress Scores

    Perceived stress will be assessed using the 10-item Perceived Stress Scale (PSS-10). The total score ranges from 0 to 40. Higher scores indicate higher levels of perceived stress and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

    Time frame: 12 weeks

  3. Change in Fasting Blood Glucose Levels

    Fasting blood glucose levels will be measured using standard biochemical laboratory methods after overnight fasting. Changes in fasting blood glucose levels between baseline and the end of the 12-week intervention will be evaluated.

    Time frame: 12 weeks

  4. Change in Total Cholesterol Levels

    Serum total cholesterol levels will be measured using standard biochemical laboratory methods. Changes in total cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

    Time frame: 12 weeks

  5. Change in Low-Density Lipoprotein (LDL) Cholesterol Levels

    Serum low-density lipoprotein (LDL) cholesterol levels will be measured using standard biochemical laboratory methods. Changes in LDL cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

    Time frame: 12 weeks

  6. Change in High-Density Lipoprotein (HDL) Cholesterol Levels

    Serum high-density lipoprotein (HDL) cholesterol levels will be measured using standard biochemical laboratory methods. Changes in HDL cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

    Time frame: 12 weeks

  7. Change in Triglyceride Levels

    Serum triglyceride levels will be measured using standard biochemical laboratory methods. Changes in triglyceride levels between baseline and the end of the 12-week intervention will be evaluated.

    Time frame: 12 weeks

  8. Change in Aspartate Aminotransferase (AST) Levels

    Serum aspartate aminotransferase (AST) levels will be measured using standard biochemical laboratory methods. Changes in AST levels between baseline and the end of the 12-week intervention will be evaluated.

    Time frame: 12 weeks

  9. Change in Alanine Aminotransferase (ALT) Levels

    Serum alanine aminotransferase (ALT) levels will be measured using standard biochemical laboratory methods. Changes in ALT levels between baseline and the end of the 12-week intervention will be evaluated.

    Time frame: 12 weeks

  10. Change in Serum Uric Acid Levels

    Serum uric acid levels will be measured using standard biochemical laboratory methods. Changes in serum uric acid levels between baseline and the end of the 12-week intervention will be evaluated.

    Time frame: 12 weeks

  11. Change in Serum Urea Levels

    Serum urea levels will be measured using standard biochemical laboratory methods. Changes in serum urea levels between baseline and the end of the 12-week intervention will be evaluated.

    Time frame: 12 weeks

  12. Change in Serum Creatinine Levels

    Serum creatinine levels will be measured using standard biochemical laboratory methods. Changes in serum creatinine levels between baseline and the end of the 12-week intervention will be evaluated.

    Time frame: 12 weeks

07

Study locations

1 site
  • Türkiye Turing ve Otomobil Kurumu
    Istanbul, 34100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers due to privacy and confidentiality considerations. Data will be used solely for the purposes of this study and will be handled in accordance with applicable data protection regulations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Of 81 non-industry interventional studies with no phase under Mental Fatigue, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's planned 3 months is below that.

Counting every sponsor, half of 93 studies reached it within 8 months; a quarter within 3 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950293
Lead sponsor
Halic University
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Kübra Salt Soğukoğlu, MSc
Contact
23151010971@ogr.halic.edu.tr
+90 554 723 96 34
Ahmet Murat Günal, PhD
principal investigator · Haliç University
Murat Baş, PhD
principal investigator · Acibadem University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion